UPC Universe Pharmaceuticals Inc
Listings ·
A 10-into-1 share consolidation takes effect only if the Class A bid price is below $1.00 for three consecutive trading days within 12 months. The 6-K gives no current share price and does not say whether Nasdaq has sent a notice.
The net loss widened to $3.3 million as third-party sales fell. Cash rose to $47,272,851, mainly because of a $15,000,000 share issue and related-party borrowings.
The company is already before a Nasdaq Hearings Panel over a separate rule, 5550(a)(2). It says it will ask for a stay of the suspension and is working on the report.
The company expects a net loss of about $20.33 million for the year ended September 30, 2024, up from $6.16 million a year earlier.
| Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 |
|---|---|---|
| Revenue | $17.86 billion | $23.02 billion |
| Research and development | $671.8 million | $3.03 billion |
| Net income (loss) | -$3.67 billion | -$8.73 billion |
| Cash from operations | -$5.05 billion | -$9.51 billion |
| Cash and equivalents | $33.59 billion | $29.50 billion |
Our latest story on this, dated Feb 25, 2025: "Universe Pharmaceuticals gets Nasdaq delisting notice over delayed Form 20-F". The story links the filing or release it is based on. Read the story.
Universe Pharmaceuticals Inc trades under the ticker UPC on NASDAQ.
Universe Pharmaceuticals Inc is listed on NASDAQ.
The SEC Central Index Key (CIK) for Universe Pharmaceuticals Inc is 1809616. Its filings are on SEC EDGAR.
563,338 shares as of 2025-09-30, per the cover page of its 20-F filed 2026-01-29.
Our directory records Universe Pharmaceuticals Inc under China.
Our directory classifies Universe Pharmaceuticals Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Universe Pharmaceuticals Inc is KYG9442G1385.
aibio.space lists Universe Pharmaceuticals Inc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as F4.
$17.86 billion for the fiscal year ended Sep 30, 2025, as reported to the SEC.
Universe Pharmaceuticals Inc reported a net loss of $3.67 billion for the fiscal year ended Sep 30, 2025, and used $5.05 billion of cash in operations, per its annual report to the SEC.
$671.8 million in the fiscal year ended Sep 30, 2025, per its annual report.
$33.59 billion in cash at Sep 30, 2025, per its 20-F.
Our latest story on Universe Pharmaceuticals, dated Oct 6, 2026: "Universe Pharmaceuticals holders approve conditional 10-into-1 share consolidation". A 10-into-1 share consolidation takes effect only if the Class A bid price is below $1.00 for three consecutive trading days within 12 months. The 6-K gives no current share price and does not say whether Nasdaq has sent a notice. Source.
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio